LIFECORE BIOMEDICAL, INC. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
LIFECORE BIOMEDICAL, INC. (LFCR) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $385.00 thousand for the 3-month period ending 2024-11-24, per its 10-Q filed 2025-01-02.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2025-01-02
- LIFECORE BIOMEDICAL, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2024-11-24 was $385.00K, a 3108.33% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2024-08-25 was $589.00K, a 1208.89% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2024-02-25 was $42.00K, a 35.38% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-11-26 was $12.00K, a 91.55% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $152.00K, a 44.53% decline from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $274.00K, a 65.27% decline from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2022 was $789.00K, a 94.81% increase from fiscal 2021.
- LIFECORE BIOMEDICAL, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2021 was $405.00K, a 91.04% increase from fiscal 2020.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2024-11-24 | $385.00K 10-Q · filed 2025-01-02 | $974.00K derived: sum of 2 quarters · filed 2025-01-02 | ||
| 2024-08-25 | $589.00K 10-Q · filed 2025-01-02 | |||
| 2024-05-26 | $152.00K 10-K · filed 2024-08-26 | |||
| 2024-02-25 | $42.00K 10-Q · filed 2024-08-09 | $54.00K derived: sum of 2 quarters · filed 2025-01-02 | $99.00K derived: sum of 3 quarters · filed 2025-01-02 | |
| 2023-11-26 | $12.00K 10-Q · filed 2025-01-02 | $57.00K derived: sum of 2 quarters · filed 2025-01-02 | ||
| 2023-08-27 | $45.00K 10-Q · filed 2025-01-02 | |||
| 2023-05-28 | $274.00K 10-K · filed 2024-08-26 | |||
| 2023-02-26 | $65.00K 10-Q · filed 2024-08-09 | $207.00K derived: sum of 2 quarters · filed 2024-08-09 | $274.00K derived: sum of 3 quarters · filed 2024-08-09 | |
| 2022-11-27 | $142.00K 10-Q · filed 2024-08-09 | $209.00K derived: sum of 2 quarters · filed 2024-08-09 | ||
| 2022-08-28 | $67.00K 10-Q · filed 2024-08-09 | |||
| 2022-05-29 | $789.00K 10-K · filed 2024-08-26 | |||
| 2022-02-27 | $6.00K 10-K · filed 2024-03-20 | $90.00K derived: sum of 2 quarters · filed 2024-03-20 | $518.00K derived: sum of 3 quarters · filed 2024-03-20 | |
| 2021-11-28 | $84.00K 10-K · filed 2024-03-20 | $512.00K derived: sum of 2 quarters · filed 2024-03-20 | ||
| 2021-08-29 | $428.00K 10-K · filed 2024-03-20 | |||
| 2021-05-30 | $405.00K 10-K · filed 2024-03-20 | |||
| 2021-02-28 | $0.00 10-Q · filed 2022-04-07 | $215.00K derived: sum of 2 quarters · filed 2024-03-20 | $297.00K derived: sum of 3 quarters · filed 2024-03-20 | |
| 2020-11-29 | $215.00K 10-K · filed 2024-03-20 | $297.00K derived: sum of 2 quarters · filed 2024-03-20 | ||
| 2020-08-30 | $82.00K 10-K · filed 2024-03-20 | |||
| 2020-05-31 | $212.00K 10-K/A · filed 2023-03-16 | |||
| 2020-02-23 | $45.00K 10-Q · filed 2021-04-08 | $120.00K derived: sum of 2 quarters · filed 2021-04-08 | $175.00K derived: sum of 3 quarters · filed 2021-04-08 | |
| 2019-11-24 | $75.00K 10-Q · filed 2021-04-08 | $130.00K derived: sum of 2 quarters · filed 2021-04-08 | ||
| 2019-08-25 | $55.00K 10-Q · filed 2021-04-08 | |||
| 2019-05-26 | $700.00K 10-K · filed 2021-07-29 | |||
| 2019-02-24 | $95.00K 10-Q · filed 2020-04-03 | $332.00K derived: sum of 2 quarters · filed 2020-04-03 | $342.00K derived: sum of 3 quarters · filed 2020-04-03 | |
| 2018-11-25 | $237.00K 10-Q · filed 2020-04-03 | $247.00K derived: sum of 2 quarters · filed 2020-04-03 | ||
| 2018-08-26 | $10.00K 10-Q · filed 2020-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |